New data were presented at the American Society of Clinical Oncology meeting in June 2010 in Chicago regarding the role of axillary management in the treatment of early stage breast cancer. Join Dr. Harold Burstein as he leads a multidisciplinary case discussion that confronts the question of how these new data may alter your practice now or in the future. Joining Dr. Burstein, an oncologist, are Dr. Jennifer Bellon, MD, an interventional radiologist, and Dr. Mehra Golshan, a surgeon. This course is part of the The Advanced Certificate Program in Breast Cancer Management III.
Part 5. Conclusion30/09/2010 Duration: 460h00s
Drs. Burstein, Bellon, and Golshan provide key takeaway messages from their discussion, including how these presented data may alter clinical practice now and in the future and contribute to the goal of tailored therapy.
Part 4. Sensitivity Analysis30/09/2010 Duration: 620h00s
Drs. Burstein, Bellon, and Golshan consider a number of patient and clinical variables that influence decisions regarding management strategy.
Part 3. Adjuvant Radiotherapy and Additional Diagnostics30/09/2010 Duration: 486h00s
The panel discusses the role of adjuvant radiotherapy and additional diagnostics, including immunohistochemistry and imaging studies, in axillary management of early-stage breast cancer.
Part 2. ACOSOG Z0011: Complete Dissection versus Sentinel Lymph Node Dissection30/09/2010 Duration: 594h00s
Dr. Jennifer Bellon, a radiation oncologist, and Dr. Mehra Golshan, a surgeon, discuss the findings of the ACOSOG Z0011 trial, which compared complete dissection to sentinel lymph node dissection in terms of survival and recurrence.
Part 1. Case Presentation and Historical Risk Assessment30/09/2010 Duration: 615h00s
After introducing the faculty, Dr. Harold Burstein presents a case that illustrates the role of axillary management in the treatment of early-stage breast cancer in light of historical risk assessment and new data presented at the 2010 ASCO meeting.